Sign In
NASDAQ:CTSO
Cytosorbents Corporation Stock Earnings Reports
$1.02
+0.0100 (+0.99%)
At Close: Apr 16, 2025
Cytosorbents Earnings Calls
Q1 2025
(Upcoming)
| Release date | May 08, 2025 |
| EPS estimate | -$0.0800 |
| EPS actual | - |
| Revenue estimate | 9.007M |
| Revenue actual | - |
| Expected change | +/- 7.36% |
Q4 2024
Beat
-$0.0300 (57.14%)
| Release date | Mar 31, 2025 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0300 |
| EPS Surprise | 57.14% |
| Revenue estimate | 10.086M |
| Revenue actual | 9.15M |
| Revenue Surprise | -9.28% |
Q3 2024
Missed
-$0.0800 (-14.29%)
| Release date | Nov 07, 2024 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0800 |
| EPS Surprise | -14.29% |
| Revenue estimate | 9.453M |
| Revenue actual | 8.613M |
| Revenue Surprise | -8.89% |
Q2 2024
Beat
-$0.0800 (11.11%)
| Release date | Aug 13, 2024 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0800 |
| EPS Surprise | 11.11% |
| Revenue estimate | 9.68M |
| Revenue actual | 9.895M |
| Revenue Surprise | 2.22% |
Last 4 Quarters for Cytosorbents
Below you can see how CTSO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Beat
| Release date | Aug 13, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $0.90 |
| EPS estimate | -$0.0900 |
| EPS actual | -$0.0800 |
| EPS surprise | 11.11% |
| Date | Price |
|---|---|
| Aug 07, 2024 | $1.09 |
| Aug 08, 2024 | $1.04 |
| Aug 09, 2024 | $1.05 |
| Aug 12, 2024 | $0.89 |
| Aug 13, 2024 | $0.90 |
| Aug 14, 2024 | $0.97 |
| Aug 15, 2024 | $1.02 |
| Aug 16, 2024 | $1.04 |
| Aug 19, 2024 | $1.05 |
| 4 days before | -17.89% |
| 4 days after | 17.32% |
| On release day | 7.99% |
| Change in period | -3.67% |
Q3 2024
Missed
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $0.90 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0800 |
| EPS surprise | -14.29% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $1.00 |
| Nov 04, 2024 | $0.87 |
| Nov 05, 2024 | $0.86 |
| Nov 06, 2024 | $0.92 |
| Nov 07, 2024 | $0.90 |
| Nov 08, 2024 | $0.740 |
| Nov 11, 2024 | $0.93 |
| Nov 12, 2024 | $0.97 |
| Nov 13, 2024 | $0.93 |
| 4 days before | -9.70% |
| 4 days after | 2.54% |
| On release day | -18.05% |
| Change in period | -7.41% |
Q4 2024
Beat
| Release date | Mar 31, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $1.00 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0300 |
| EPS surprise | 57.14% |
| Date | Price |
|---|---|
| Mar 25, 2025 | $1.04 |
| Mar 26, 2025 | $1.02 |
| Mar 27, 2025 | $1.00 |
| Mar 28, 2025 | $1.00 |
| Mar 31, 2025 | $1.00 |
| Apr 01, 2025 | $1.00 |
| Apr 02, 2025 | $1.00 |
| Apr 03, 2025 | $0.99 |
| Apr 04, 2025 | $0.97 |
| 4 days before | -3.85% |
| 4 days after | -3.00% |
| On release day | 0% |
| Change in period | -6.73% |
Q1 2025
(Upcoming)
| Release date | May 08, 2025 |
| Fiscal end date | Mar 30, 2025 |
| Price on release | - |
| EPS estimate | -$0.0800 |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 10, 2025 | $0.94 |
| Apr 11, 2025 | $0.97 |
| Apr 14, 2025 | $0.99 |
| Apr 15, 2025 | $1.01 |
| Apr 16, 2025 | $1.02 |
Cytosorbents Earnings Call Transcript Summary of Q4 2024
Adjusted EBITDA loss improved by 70% to $2.4 million.
Cash Position: As of December 31, 2024, cash and cash equivalents stood at approximately $9.8 million, increasing to around $17 million on a pro forma basis, benefiting from a recent rights offering.
Product and Market Highlights
- CytoSorb Product: Over 270,000 devices used in 70+ countries, primarily addressing severe inflammation in critical care settings. 2024 sales driven by a 28% increase in direct international sales, despite flat growth in Germany.
- DrugSorb-ATR: Investigational device aimed at reducing perioperative bleeding in CABG surgery, submitted for regulatory approval in the U.S. and Canada. The total addressable market is projected to grow from $300 million to over $1 billion as the blood thinner Brilinta becomes generic.
Regulatory Updates
- FDA and Health Canada Applications: The FDA de novo application for DrugSorb-ATR is under interactive review, with anticipated approvals in 2025. Health Canada’s application is also in an advanced review stage.
Operational Strategies and Market Development
- Reorganization in Germany: Aimed at overcoming stagnant sales by enhancing customer engagement and overall sales team productivity, with short-term disruptions expected but longer-term growth anticipated.
- Sales Growth Strategy: Education on optimal treatment protocols for CytoSorb is expected to enhance adoption and utilization, particularly in severe inflammation cases.
Future Outlook
- Near-Term Goals: Targeting near cash flow breakeven by the end of 2025, primarily through sustainable revenue growth and improved cost management.
- Potential Launch of DrugSorb-ATR: Expected controlled market release and broader launch thereafter, with ongoing clinical data presentations aimed at building awareness and supporting sales efforts.
- Market Dynamics: Despite current challenges in Germany, overall international growth is strong, and potential regulatory approvals could provide significant market opportunities.
Conclusion
Investors should note CytoSorbents is on a path toward enhanced financial performance driven by sustained product demand and upcoming regulatory approvals for DrugSorb-ATR, which could unlock new revenue streams. The focus on operational efficiency and market development positions the company for potential long-term growth, underscoring its expanding role in critical care and cardiac surgery.
Cytosorbents Earnings History
Earnings Calendar
FAQ
When is the earnings report for CTSO?
Cytosorbents Corporation (CTSO) has scheduled its earnings report for May 08, 2025 before the markets open.
What is the CTSO price-to-earnings (P/E) ratio?
CTSO P/E ratio as of Apr 16, 2025 (TTM) is -2.61.
What is the CTSO EPS forecast?
The forecasted EPS (Earnings Per Share) for Cytosorbents Corporation (CTSO) for the first fiscal quarter 2025 is -$0.0800.
What are Cytosorbents Corporation's retained earnings?
On its balance sheet, Cytosorbents Corporation reported retained earnings of $9.15 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
